Changeflow GovPing Healthcare & Life Sciences Patent Application for Stabilized Galectin-9 Pr...
Routine Notice Added Draft

Patent Application for Stabilized Galectin-9 Protein Pharmaceutical Formulation

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has published a patent application (US20260083671A1) for a stabilized pharmaceutical formulation containing a recombinant stabilized galectin-9 protein. The application details a formulation designed for improved stability through the combination of a buffer and a stabilizer.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO detailing a novel pharmaceutical formulation. The application, filed on August 8, 2025, and published as US20260083671A1, describes a stabilized formulation comprising a recombinant stabilized galectin-9 protein, specifically designed for improved stability through the combination of a buffer and a stabilizer.

This publication represents a new intellectual property filing related to drug formulation. While not a regulatory rule, it signals potential future developments in therapeutic products. Companies in the pharmaceutical sector should be aware of this filing as it pertains to potential new drug compositions and may impact their own research and development or patent strategies.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

STABILIZED FORMULATION COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN

Application US20260083671A1 Kind: A1 Mar 26, 2026

Inventors

David SONG

Abstract

The present invention relates to a stabilized pharmaceutical formulation comprising a recombinant stabilized galectin-9 protein. More specifically, the invention provides a pharmaceutical formulation with improved stability through the combination of a buffer and a stabilizer.

CPC Classifications

A61K 9/08 A61K 9/19 A61K 38/1732 A61K 47/02 A61K 47/12 A61K 47/183 A61K 47/22 A61K 47/26

Filing Date

2025-08-08

Application No.

19295090

View original document →

Named provisions

STABILIZED FORMULATION COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
August 8th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083671A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Formulation Protein Stabilization
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Intellectual Property Drug Development

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!